STHLM3 - Prostate Cancer Diagnostic Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03639649

Acronym

STHLM3

Enrollment

58818

Registered

2018-08-21

Start date

2013-08-31

Completion date

2015-02-28

Last updated

2018-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer

Interventions

DIAGNOSTIC_TESTSTHLM3

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

50 Years to 69 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 50-69 * Residential address in Stockholm County

Exclusion criteria

* Previous Prostate Cancer Diagnosis * Not able to comprehend inform consent material

Design outcomes

Primary

Measure	Time frame
Number of biopsies	Recorded directly after biopsy

Secondary

Measure	Time frame
Number of Gleason Score ≥ 7	Recorded directly after biopsy
Number of Gleason Score 6	Recorded directly after biopsy
Number of benign	Recorded directly after biopsy

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026